Search Results

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.

• Authors : Della Porta MG; Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy. Electronic address: .

Subjects: Epoetin Alfa*/Epoetin Alfa*/Epoetin Alfa*/therapeutic use ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/complications ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy

• Source: The Lancet. Haematology [Lancet Haematol] 2024 Sep; Vol. 11 (9), pp. e646-e658. Date of Electronic Publication: 2024 Jul 19.Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Education Full Text (H.W. Wilson)

Record details

Initial experiences with combined therapy of anemia with roxadustat and epoetin α in hemodialysis patients: a case series.

• Authors : Biedunkiewicz B; Jankowska M; Komorniczak M

Subjects: Renal Dialysis* ; Anemia*/Anemia*/Anemia*/drug therapy ; Anemia*/Anemia*/Anemia*/etiology

• Source: Polish archives of internal medicine [Pol Arch Intern Med] 2024 Sep 27; Vol. 134 (9). Date of Electronic Publication: 2024 Sep 24.Publisher: Medycyna Praktyczna Country of Publication: Poland NLM ID: 101700960 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Pharmacokinetic and pharmacodynamic study of three products of epoetin alfa as single subcutaneous dose in healthy volunteers.

• Authors : di Girolamo G; Department of Toxicology and Pharmacology, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina.; Keller GA

Subjects: Erythropoietin*; Humans ; Epoetin Alfa/Epoetin Alfa/Epoetin Alfa/pharmacokinetics

• Source: Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2023 Jun; Vol. 37 (3), pp. 651-662. Date of Electronic Publication: 2023 Feb 10.Publisher: Blackwell Science Country of Publication: England NLM ID: 8710411 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Pharmacist-driven epoetin alfa-epbx dosing for hospitalized patients.

• Authors : Linn E; Department of Pharmacy, Health First Holmes Regional Medical Center, Melbourne, FL, USA.; Morrison H

Subjects: Erythropoietin* ; Hematinics*; Humans

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2023 May 24; Vol. 80 (11), pp. 687-691.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience.

• Authors : Gascón P; Division of Medical Oncology, IDIBAPS, Hospital Clinic, Casanova 143, 08036 Barcelona, Spain.; Goldsmith D

Subjects: Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/adverse effects ; Erythropoietin*/Erythropoietin*/Erythropoietin*/adverse effects ; Hematinics*/Hematinics*/Hematinics*/adverse effects

• Source: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2023 Jan; Vol. 181, pp. 103894. Date of Electronic Publication: 2022 Dec 05.Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Fatigue visual analogue scale score correlates with quality of life in cancer patients receiving epoetin alfa (Sandoz) for chemotherapy-induced anaemia: The CIROCO study.

• Authors : Desramé J; Institut Privé de Cancérologie, Hôpital Privé Jean Mermoz, 55 Av. Jean Mermoz, 69373, Lyon 69008, France. Electronic address: .; Baize N

Subjects: Erythropoietin*/Erythropoietin*/Erythropoietin*/therapeutic use ; Erythropoietin*/Erythropoietin*/Erythropoietin*/adverse effects ; Hematinics*/Hematinics*/Hematinics*/therapeutic use

• Source: Cancer treatment and research communications [Cancer Treat Res Commun] 2023; Vol. 37, pp. 100781. Date of Electronic Publication: 2023 Nov 23.Publisher: Elsevier Country of Publication: England NLM ID: 101694651 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-2942

Record details

The influencing factors of the erythropoietin resistance index and its association with all-cause mortality in maintenance hemodialysis patients.

• Authors : Zhao X; Department of Nephrology, Peking University People's Hospital, Beijing, China.; Gan L

Subjects: Anemia*/Anemia*/Anemia*/etiology ; Erythropoietin*/Erythropoietin*/Erythropoietin*/therapeutic use ; Hematinics*/Hematinics*/Hematinics*/therapeutic use

• Source: Renal failure [Ren Fail] 2024 Dec; Vol. 46 (1), pp. 2290922. Date of Electronic Publication: 2024 Jan 17.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8701128 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Correlation between ultrafiltration rate and hemoglobin level and erythropoietin response in hemodialysis patients.

• Authors : Cui L; Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, China.; Zhang L

Subjects: Kidney Failure, Chronic* ; Erythropoietin*/Erythropoietin*/Erythropoietin*/therapeutic use ; Anemia*

• Source: Renal failure [Ren Fail] 2024 Dec; Vol. 46 (1), pp. 2296609. Date of Electronic Publication: 2024 Jan 04.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8701128 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States.

• Authors : Anand S; Division of Hematology & Oncology, University of California , Santa Monica, CA, USA.; Al-Mondhiry J

Subjects: Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*administration & dosage ; Epoetin Alfa/Epoetin Alfa/Epoetin Alfa/*administration & dosage ; Hematinics/Hematinics/Hematinics/*administration & dosage

• Source: Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2021 Jan; Vol. 14 (1), pp. 1-8. Date of Electronic Publication: 2020 Dec 27.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101278296 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details